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assess the characteristics of geriatric patients diagnosed with MS and taking dis-
ease modifying therapies (DMTs) in the US. Methods: A large US administrative 
retrospective claims database was used to identify patients diagnosed with MS 
and were prescribed DMTs between January 2010 to December 2012 were included 
in the study. All patients were ≥ 65 years of age and continuously enrolled in the 
same health plan for at least a year. Descriptive statistics and chi-square tests 
were performed on the data and statistical significance level was set a priori at 
0.05. Results: There were a total of 88,921 patients that met the study inclusion 
criteria. Of these, 67,335 (75.7%) were females, mean age was 68.2±3.4years, and 
majority of the patients were between 65 and 75 years of age (95.4%). Thirty five 
percentage of the patients were from Midwest, 31.6% were from East, 22% from 
south and 11.4% from West of the USA. Majority (66.9%) of the patients was taking 
subcutaneous injections, 31.2% were taking IV/IM and 1.9% was taking oral DMTs 
(p< 0.001). 48.8% of the patients was under a group coverage, 58.8% of the patients 
were taking a DMT that was under their health plan formulary with a significant 
variation between the groups (p< 0.001). The mean number of days of DMT supply 
was 33.3±16.1 with a significant difference between the three groups (p< 0.001). 
Females enrolled continuously 5.5 ± 3.4 years with mean total number claims of 
637.1±504.7 during the study period. ConClusions: Majority of the patients taking 
DMTs was females and was between 65 and 75 years of age. Most of the patients 
were taking subcutaneous injections compared to other forms of DMTs.
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objeCtives: According to the IRAN NCRUM (National Committee Rational Use 
of Medicine) reports, assuming each prescription as an individual patient, 45% of 
patients received antibiotics. Decreasing of infections in the school community by 
improving of hygiene lead to decrement of consumption of antibiotics in children. 
The objective of this study was to assess the impact of the effectiveness of the 
puppet plays in improving children’s knowledge about hand washing and using 
normal saline to Rinse nose and throat to decrease the spread of infection and 
unnecessary antibiotic use. Methods: Evaluation was undertaken with 4 grade 
students (10 years) in primary schools in Fasa. 200 Students watched puppet plays 
in 5 groups which each groups contain 40 students. During the experiment, 2 puppet 
shows were used in one day. Then Students were required to complete identical 
knowledge questionnaires at two time points (before, and immediately after pup-
pet show), to assess knowledge change. The questionnaires had 4 type questions 
include: group 1 about story, group 2 about hand washing, group 3 about how to use 
normal saline and group 4 about rational use of medicine. Results: Our results 
demonstrated a significant improvement in student’s knowledge in all groups after 
puppet plays (P< 0.0001). ConClusions: Although the puppet plays has significant 
improve in knowledge of the students, modifications are needed in puppet plays 
for more achievement.
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objeCtives: This paper identifies factors that affect the cost and performance of 
the routine immunization program in Moldova through an analysis of facility-based 
data collected as part of a multi-country costing and financing study of routine 
immunization (EPIC). Methods: A nationally representative sample of health care 
facilities (50) was selected through multi-stage, stratified random sampling. Data 
on inputs, unit prices and facility outputs were collected during October 3rd 2012–
January 14th 2013 using a pre-tested structured questionnaire. Ordinary least square 
(OLS) regression analysis was performed to determine factors affecting facility out-
puts (number of doses administered and fully immunized children) and explaining 
variation in total facility costs. Results: The study found that the number of work-
ing hours, vaccine wastage rates, and whether or not a doctor worked at a facility 
(among other factors) were positively and significantly associated with output levels. 
In addition, the level of output, price of inputs and share of the population with 
university education were significantly associated with higher facility costs. A 1% 
increase in fully immunized child would increase total cost by 0.7%. ConClusions: 
Few costing studies of primary health care services in developing countries evaluate 
the drivers of performance and cost. This exercise attempted to fill this knowledge 
gap and helped to identify organizational and managerial factors at a primary care 
district and national level that could be addressed by improved program manage-
ment aimed at improved performance.
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objeCtives: Characterize the temporal course of psychiatric healthcare utiliza-
tion and related costs in a cohort of newly diagnosed ASD individuals. Methods: 
A cohort was built using RAMQ databases. Newly diagnosed subjects with ASD were 
selected (≥ 2 diagnoses ICD-9 codes: 299.X, excluding 299.2) between January 1998 and 
December 2010. Cohort entry was the date of first diagnosis confirmed by absence 
of ASD diagnosis in previous 5 years. Participants aged ≥ 26 years, those without 
full RAMQ drug plan coverage for 5 years after cohort entry, or not covered in the 
year preceding cohort entry were excluded. Demographic and clinical characteris-
all the four nationwide datasets together at the end of the study period, the most 
common drug groups used in children were antibacterials for systemic use (ATC 
group J01), ophthalmologicals (S01) and drugs for obstructive airway diseases (R03). 
The most common individual drugs were phenoxymethylpenicillin, amoxicillin 
and salbutamol. The drug consumption increased remarkably at the age of one 
year, and decreases then by school-age. Drugs were more commonly used in boys 
than in girls, but this difference vanished along age. The use of psychoanaleptics, 
methylphenidate in particular, increased in all countries during the study period. 
Also drugs used for constipation became more common. Decreases were noticed 
among antiobstructive, antiinflammatory and antirheumatic drugs. No remarkable 
between-country differences were observed within this cohort of about 4.4 million 
children. We saw, however, some differences in practices to prescribe drugs used for 
allergic symptoms. ConClusions: The national registers in the Nordic countries 
have exquisite potential as data sources for high quality and cost-effective pharma-
coepidemiological studies. We indicated that Nordic citizens form an outstanding 
large and homogenous population for outpatient studies also in children. Future 
plans aim to survey use of contraindicated drugs in children.
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objeCtives: Studies reporting on the prescribing patterns of anti-dementia medi-
cine in South Africa are scarce and most studies have been conducted on medical 
aid claims databases. The primary aim of this study was to determine the dispens-
ing patterns and cost of anti-dementia medicine from a community pharmacy 
perspective. Methods: A retrospective pharmacoepidemiological study was con-
ducted on community pharmacy dispensing records in South Africa for 2013. All 
products in ATC subgroup N06D were extracted and analysed. Results: A total of 
12 307 products were dispensed to 2 244 patients. The average age of patients was 
72.83 (SD= 13.30) years. Slightly more males (53.07%) were prescribed anti-dementia 
products, they were prescribed 55.68% of anti-dementia products, and they were 
slightly older than female patients (74.40 versus 71.05 years). Four different active 
ingredients were prescribed, with donepezil the most often dispensed (61.58%), 
followed by memantine (27.81%). Only 1 278 prescriptions for galantamine were 
dispensed, and 27 prescriptions for rivastigmine. Rivastigmine was on average 
the most expensive per prescription (R856.68), followed by galantamine (R713.22), 
memantine (R532.79) and donepezil (R330.30). Donepezil was the only active ingredi-
ent with a generic equivalent (the average cost of the branded generic product was 
R303.58, compared to R485.72 for the originator product). Only 76.38% of products 
were partly or fully claimed from various medical aid schemes, the rest were paid 
for privately. Prescribing of combination therapy was not common. Only 5.57% of 
patients received more than one anti-dementia active ingredient during the year, 
and mostly not simultaneously. Most prescriptions (84.85%) were repeat prescrip-
tions. ICD-10 codes were not specific. ConClusions: The cost of the branded 
generic of donepezil was 62.50% of the cost of the originator product. This finding 
was in agreement with other South African studies on generic prescribing. Further 
studies should focus on the impact of anti-dementia medicine on the quality of 
life of patients.
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objeCtives: Despite advancements in the healthcare system and availability of sev-
eral guidelines for appropriate prescribing, inappropriate drug prescription remains 
a noteworthy problem among older adults. Therefore, this study designed to identify 
inappropriate drug prescriptions and their predictors in older adults. Methods: 
Prospective cohort study included 142 outpatients aged 60 years or over, of both 
sexes. Identified inappropriate drug prescription using the Modified Updated AGS 
Beers Criteria 2012 and also identified associated predictors. Results: The patients 
had an average age (±SD) of 69.8±7.4 years and on an average (±SD) were prescribed 
4.7±1.6 medications. Twenty three patients received at least one inappropriate drug 
(16.2%). 29 potentially inappropriate drugs were identified in 142 patients. Therefore, 
the total inappropriate drug use was found to be 20.42% (29/142). The most common 
inappropriate classes/drugs according to the first list of AGS Beers criteria 2012 were 
aspirin, prazosin, diclofenac, methyldopa and nifedipine. According to the second 
list were prazosin in syncope, followed by aspirin in bleeding and chlorphenara-
mine in chronic constipation. Increased inappropriate prescription was likely to 
be associated with patients with a advanced age of > 74 years (OR-2.5; p< 0.05) and 
number of diagnosis (OR-2.38, p< 0.05). ConClusions: The assessment of inap-
propriate drug prescription has shown a lower prevalence (16.2%) as compared with 
other countries (up to 87%). Although lower prevalence, drug monitoring and educa-
tion to physicians, other healthcare professionals and patients required to reduce 
inappropriate drug prescription to avoid any adverse effects among older patients. 
Despite advancements in healthcare system and availability of several guidelines 
for appropriate prescribing, inappropriate drug prescription remains noteworthy 
problem among older adults. Therefore, this study designed to identify inappropriate 
drug prescriptions and their predictors in older adults.
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objeCtives: Understanding the heterogeneous characteristics of Multiple sclerosis 
(MS) patients is not properly studied in the past. The objective of this study is to 
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objeCtives: The telemedicine is developing rapidly, but the integration of IT 
capabilities of e-Health in clinical practice is not so fast. Aim. To create an inte-
grated health information system for pediatrics according to results of research in 
e-Health. Methods: 40 publications, 2 meta-analyses regarding the use of remote 
monitoring in healthcare from 2001 to 2014 y. were reviewed on the following top-
ics: • establishment of the remote collection of patient data; • automatic analysis 
of clinical data. Results: The studied systems were divided into 3 groups in terms 
of the integration of data mining in order to diagnose or predict exacerbations: • 
organizing the collection and analyzing of data with the module; • no organizing 
the collection, but implementing data analysis for a narrow range of diseases; • 
organizing the collection and analyzing of the data for realizing a narrow range of 
diseases. The evaluation of the proposed options for the transfer of data to their 
storage and analyses was conducted. Medical data system with integrated part of 
telemedicine is able to generate a huge stream of data, in which a simple analysis 
of the data on the local device aggregates (smartphone) can be used. For data 
storage organization is natural to use a relational database management system, 
and for the exchange of information - a standardized platform-independent pro-
tocols. ConClusions: We propose the architecture of remote health monitoring 
and analytic system, in which in addition to the function of collecting patients 
data is a subsystem of patient monitoring, designed for an automatic assessment 
of the health indices and patient state. The study was supported by the Russian 
Foundation for Basic Research, the project ¹ 13-04-12055.
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objeCtives: To examine an organization-wide strategy for improving continu-
ity of care across the hospital-community interface for older internal medicine 
patients, including: Automated predictive modeling, Reaching out to patients, 
and Monitoring. Methods: The comprehensive strategy includes a data-driven 
high-risk patient identification algorithm, classifying all older Clalit enrollees (65+) 
according to their a-priori risk for readmission (scores range 0-100); a nurse–led 
intervention to target high risk patients in all general hospitals in Israel providing 
discharge planning intervention, coupled with a primary care clinic nurse reach-out 
intervention to assess post-discharge needs; and monitoring through standardized 
reports to all primary care clinics. We examined rate of visits with primary care 
provider within 3 days after discharge and rate of lack visits within 7 days after 
discharge. Results: We developed the Preadmission Readmission Detection Model 
(PREADM), a unique real-time admission risk identification algorithm, which exhib-
ited good predictive accuracy (c-stat = 0.69). On average 6,563 high-risk patients 
were targeted for in-hospital and primary care interventions each year. In 2012, 
the rate of primary care visits within 3 days after discharge was less than 50% and 
in 2013 and 2014 this rate increased to 62.1% and 66%, respectively. The rate of lack 
visits within 7 days after discharge also improved from 35% to 14% in 2012, 2013 
and 2014, respectively. ConClusions: Feasibility of a large-scale organization-
wide strategy transitional care for high-risk older Clalit patients (in any hospital 
as well as in all community clinics) was established. Our results on improvement 
in early primary care follow-up after discharge indicate a significant improvement 
in continuity of care.
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objeCtives: Readmission reduction is at the focus of health care systems 
worldwide in efforts to improve efficiency across care settings. Patients’ reports 
of their hospital to community transitional care experience are an important 
tool to detect breakdowns along the care continuum. We aimed to examine the 
relationship between patients’ reports on the experience of their transitional 
care process and the risk of readmissions. Methods: A retrospective cohort 
study based on data of hospitalized members of Clalit, Israel’s largest inte-
grated health care provider and non-for-profit payer. Participants were aged 65 
and older, admitted to internal medicine departments between September 2012 
and February 2013. Readmission was defined as unplanned hospitalization to 
internal department or intensive care units within 30 days of discharge to any 
hospital. The Care Transition Measure (CTM) was used to evaluate patients’ tran-
sitional care experience. We examined differences in the rates of readmissions 
according to CTM scores, stratified according to a validated composite measure 
of known readmission risk factors (the Preadmission Readmission Prediction 
Model - PREADM). Results: A total of 2,626 patients completed the survey. The 
average CTM score was 85.7. Over 60% of respondents reported a good – excel-
lent transitional care experience (CTM above 80). Analysis of the difference in 
readmission rates within the high PREADM score group (10% highest score) by 
CTM score showed a 14% greater likelihood of readmission in those with medium-
low CTM scores (below 80) and those with high CTM scores (80 or higher) (22% 
and 25.5% readmission rate respectively). ConClusions: This study shows 
that high-risk patients benefit from treatment focused on the patient and the 
experience of a good discharge, with a reduced risk of 14% in readmissions 
within 30 days. These findings support previous research on the importance of 
targeting patient-centered interventions to patients with the high readmission 
risk.
tics were done at cohort entry. Descriptive use of psychiatric healthcare care (medi-
cal visits, hospitalizations, psychoactive drug use (anticonvulsants, antipsychotics, 
antidepressants, anxiolytics, ADHD drugs, anticholinergics, lithium) was assessed 
during a 5-year follow-up period. Mean costs per patient was estimated at 1- and 
5-year period of follow-up. Bootstrap analyses were used to assess the differences 
in costs between 1-year and 5-year follow-up. Results: A total of 1,227 individuals 
were identifed (male: 80.3%; median age: 7 years). In the 1-year period after diagnosis, 
mean number of psychiatric medical visits was 7.5 ± 14.6 with mean cost per patient 
of $653CAD (95%CI: 582-723); those values reduced to 2.1 ± 4.2 and $205CAD(175-
235), respectively at 5-years. Psychiatric hospitalization rate was 10.4% with mean 
cost per patient $9,717CAD(7,253-12,180) at year 1; the rate and cost reduced to 3.7% 
and $4259 CAD(2,395-6,123) at 5-years. Psychoactive drug utilization was initially 
present in 49.3% of subjects, and increased to 53.2% at 5-years. Associated mean drug 
costs per patient increased from $622CAD(539-706) to $889CAD(786-991), in this time 
period. ConClusions: While costs for psychiatric medical visits and hospitaliza-
tions decreased by more than half over 5 years, psychoactive drug costs rose by 43%. 
Access to long term care and monitoring among the ASD population is discussed.
PIH83
value assessment foR genetIC testIng of dRug vaRIatIon In an 
eldeRly PoPulatIon
Biskupiak JE1, Biltaji E1, Bress A1, Unni S1, Ye X1, Yu B1, Mamiya T2, Brixner D3
1University of Utah, Salt Lake City, UT, USA, 2Genelex, Inc, Seattle, WA, USA, 3University of Utah, 
Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, 
USA
objeCtives: To compare health resource utilization (HRU) among elderly patients 
exposed to drugs metabolized by a polymorphic drug metabolizing enzyme (DME) 
tested in a prospective registry for known drug-gene interaction risk (DGIR) vs. 
untested historical controls from Inovalon’s MORE2® database. Methods: 
A retrospective cohort of historical controls age ≥ 65 years was identified with 
continuous enrollment, taking ≥ 3 prescription medications (July 1, 2012 - March 
31, 2013) and on ≥ 1 drugs metabolized by a polymorphic DME. Subjects were 
defined as having a first claim for ≥ 1 drug with genetic implications or a dose 
change on index. Demographic, clinical and economic variables, were collected 
via prospective registry on tested patients and propensity score matching was 
conducted (matching variables: age, gender, comorbidities, and baseline medica-
tions). Patients were stratified into potential and known DGIR groups via (Genelex 
Youscript®) software. Counts of HRU during 4 months follow-up post index-date 
included all-cause hospitalizations, emergency-room and clinic visits. Results: 
Interim analysis of 205 tested patients with a mean age of 75 ± 7 (58% female) 
were compared to 82,073 historical controls (mean age 74± 6, 61% female) using 
t-test (p< 0.0001). After matching 820 historical controls to the tested cohort, the 
standardized differences among the matching variables were less than 0.05. Over 
90% of the total cohort has DGIR. The counts of total HRU reported among tested 
patients was lower compared to historical cohort (2.10 vs 2.65, respectively). Any 
DGIR was associated with lower overall HRU counts among tested groups com-
pared to controls (p= 0.005). ConClusions: Based on the interim analysis, we 
demonstrated the value of genetic testing of drug variation in an elderly popula-
tion. Higher HRU among elderly patients that were not tested may be linked to 
their DGIR. Routine genetic testing may result in lower HRU and their associated 
costs as well as improved patient care.
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objeCtives: Product labeling conveys information about the potential risks of 
medication for healthcare professionals and consumers, but the consistency (or 
inconsistency) of such information is unknown. We sought to investigate the 
consistency of information intended for healthcare professionals versus con-
sumers about cardiovascular risks from stimulants approved in four English-
speaking countries. Methods: Professional and consumer drug product labels 
were obtained in July 2014 from regulatory agencies in Australia, Canada, United 
Kingdom, and United States. Language describing the nature of the relationship 
between the drug and four major cardiovascular adverse events (elevated blood 
pressure and/or heart rate, stroke, myocardial infarction, and sudden death) was 
extracted verbatim and classified into one of four mutually exclusive categories: 
confirmed, unconfirmed, mixed and not mentioned. Results: We obtained pro-
fessional and consumer product labeling for 24 unique, approved stimulants (16 
US, 6 UK, 6 Canada, and 5 Australia). Language regarding the relationship between 
drug and cardiovascular adverse events was consistent for professional and con-
sumer audiences 54.5% of the time (59% US, 20% Australia, 58% Canada, 67% UK). 
One in three (32%) labels for professionals and consumers included inconsist-
ent language that described a drug-adverse event relationship as both confirmed 
and unconfirmed. ConClusions: Regulator approved product labeling provides 
healthcare professionals and consumers with inconsistent messages regarding the 
certainty (or uncertainty) of the relationship between stimulant use and specific 
cardiovascular risks in children and adolescents. Professionals and consumers 
often receive “mixed” messages about the actual risk of a particular cardiovas-
cular event within the same label. The implications towards patient safety and 
outcomes warrants further study.
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